Abstract: FR-PO0809
Efficacy and Kidney Outcomes of Anti-CD20 Monoclonal Antibody Therapy in Patients with Membranous Nephropathy and Concomitant Diabetic Kidney Disease: A Multicenter Cohort Study
Session Information
- Glomerular Diseases: Practice and New Concepts Shaping Modern Care
October 23, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Li, Haixia, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
- Chu, Hong, Peking University First Hospital, Beijing, China
- Cui, Zhao, Peking University First Hospital, Beijing, China
- Xing, Guangqun, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
Background
This prospective study, utilizing data from the Affiliated Hospital of Qingdao University and the Peking University Multicenter Membranous Nephropathy Database, investigated treatment responses and clinical outcomes in patients with biopsy-confirmed membranous nephropathy (MN) complicated by diabetic kidney disease (DKD), stratified by treatment strategy.
Methods
Patients with an estimated glomerular filtration rate (eGFR) ≥30 mL/min were enrolled and followed for ≥6 months. In addition to standard of care (SOC), patients were categorized into three groups: the Anti-CD20 monoclonal antibody group (n=17), the non-anti-CD20 immunosuppressive therapy (non-CD20 IST) group (n=32), and the SOC-only group (n=11). The median follow-up was 26 (24-30) months.
Results
The cumulative remission rate was significantly higher in the Anti-CD20 mAb group (41.2% at 6 months; 58.8% at 24 months) compared to the non-CD20 IST (15.6%; 21.9%, p<0.01) and SOC groups (9.1%; 9.1%, p<0.01) at both time points. Proteinuria reduction from baseline was greater in the Anti-CD20 mAb group (p<0.001) than in the non-CD20 IST (p<0.05) and SOC groups (p<0.01). Serum albumin increased significantly in both the Anti-CD20 mAb and non-CD20 IST groups (p<0.001 and p<0.05, respectively), with a more pronounced increase in the Anti-CD20 mAb group (p<0.01). While eGFR declined significantly in the non-CD20 IST (80.49±22.29 to 59.88±23.93 mL/min, p<0.001) and SOC groups (73.45±20.95 to 28.90±26.99 mL/min, p<0.001), it remained relatively stable in the Anti-CD20 mAb group (68.58±26.56 to 59.57±26.14 mL/min, p>0.05). The incidence of adverse events did not differ significantly among groups (p>0.05).
Conclusion
In patients with MN and DKD, anti-CD20 monoclonal antibody therapy confers superior renal outcomes, including higher remission rates, greater reduction in proteinuria, and better preservation of eGFR, without increasing adverse events, compared to non-CD20 immunosuppressive therapy or standard care alone.